Navigation Links
Transplanted heart made more acceptable by daclizumab

Daclizumab has been found to reduce the risk of cellular rejection after a heart transplant// when used on top of standard immunosuppression.

The drug, a humanized monoclonal antibody, is directed against the interleukin-2 receptor, thereby inhibiting T-cell proliferation.

Patients who were taken into the Study were either given daclizumab or a placebo.

The primary endpoint was a composite of moderate or severe cellular rejection, hemodynamically significant graft dysfunction, a second transplantation, or death or loss to follow-up within 6 months.

It has been reported 44.7% of patients in the placebo group reached the primary endpoint, versus just 35.6% in the daclizumab group–equivalent to a 25% relative risk reduction with the novel therapy Rejection was also less common with Daclizumab than Placebo. However, six patients receiving daclizumab died from infection when receiving concomitant cytolytic therapy compared with none in the placebo group.

When the negative aspect of daclizumab use is examined, researchers would not be willing to trade even a small increase in the risk of death from infection for a reduction in the risk of histologic rejection.


'"/>




Page: 1

Related medicine news :

1. Kidneys Can Be Transplanted From Animals Such As Pigs In Future
2. Transplanted Pancreatic Tissue Could Help Diabetics
3. MRI Can Monitor Transplanted Islets
4. White Blood Cells Can Both Hurt and Help Transplanted Kidneys
5. Study Reveals Effects of WBCs on Transplanted Kidney
6. HIV Positive Organs Transplanted
7. New Drug Mix to Extend Life of Transplanted Kidneys
8. Transplanted Pig Cells in Human Produce Insulin
9. Starvation in pregnant women can cause heart disease to their children
10. Individuals with sleep related breathing disorders more prone to heart disease
11. And now they say infections can cause heart disease!!!!
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: